Intravenous Iron Therapy for Iron Deficiency in Pregnancy
Trial Summary
What is the purpose of this trial?
Ion deficiency anemia (IDA) is associated with poor neonatal outcomes and maternal morbidity. Iron replacement may be done with oral iron or intravenous iron, with intravenous iron being utilized later in pregnancy or if there is an inadequate response to oral iron in the first trimester. In Canada, iron sucrose has been used, however iron isomaltoside is as safe as other formulations of IV iron but can replete iron stores with a single visit. Replenishing iron stores reduces both maternal and neonatal risks and is supported by current guidelines. Iron status may play a role in depression, as well as anemia, bleeding and blood transfusion. The goal of this clinical trial: * Correct IDA with fewer visits and less impact on the healthcare system * Improve the health and well being of all pregnant women who are experiencing moderate to severe iron deficiency anemia.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are currently being treated with IV iron products or have had a blood transfusion within 4 weeks prior to joining, you cannot participate.
What data supports the idea that Intravenous Iron Therapy for Iron Deficiency in Pregnancy is an effective treatment?
The available research shows that Intravenous Iron Therapy, such as iron sucrose and ferric derisomaltose, is effective in treating iron deficiency in pregnant women. Studies comparing intravenous iron to oral iron treatments, like ferrous fumarate, indicate that intravenous iron can be more effective. For example, one study found that intravenous iron sucrose increased hemoglobin levels more effectively than oral iron in pregnant women with moderate-to-severe anemia. Another study showed that ferric derisomaltose was more effective than oral iron in women with persistent iron deficiency. These findings suggest that intravenous iron therapy can be a better option for improving iron levels during pregnancy.12345
What safety data exists for intravenous iron therapy in pregnancy?
Intravenous iron therapies, including iron isomaltoside (also known as ferric derisomaltose) and iron sucrose, have been evaluated for safety in various studies. Iron isomaltoside has been shown to be well tolerated with a low incidence of serious adverse reactions (0.6%) and hypersensitivity reactions (0.3%). It also allows for higher cumulative dosing in fewer administrations compared to iron sucrose. Iron sucrose has been compared to oral iron therapies and shown to be effective, though its safety profile in pregnancy is still being established. Overall, both treatments have demonstrated a low frequency of hypersensitivity reactions and cardiovascular events, indicating a favorable safety profile for use in iron deficiency anemia, including during pregnancy.12567
Is the drug Iron Isomaltoside 1000, Iron Sucrose a promising treatment for iron deficiency in pregnancy?
Research Team
Ryan Lett, MD, FRCPC
Principal Investigator
Saskatchewan Health Authority - Regina Area
Eligibility Criteria
This trial is for pregnant women over 18 with moderate to severe iron deficiency anemia, defined by specific blood test results. They must be at least 13 weeks into their pregnancy and willing to attend all treatment and follow-up appointments. Women with kidney or heart disease, certain infections, iron utilization disorders, recent IV iron or transfusions, multiple pregnancies, serious allergies or other significant health issues are excluded.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Iron Isomaltoside 1000 (Iron Replacement Therapy)
- Iron Sucrose (Iron Replacement Therapy)
Iron Isomaltoside 1000 is already approved in United States, European Union, Canada for the following indications:
- Iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron or who have non-hemodialysis dependent chronic kidney disease (NDD-CKD)
- Iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron or who have non-hemodialysis dependent chronic kidney disease (NDD-CKD)
- Iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron or who have non-hemodialysis dependent chronic kidney disease (NDD-CKD)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Saskatchewan Health Authority - Regina Area
Lead Sponsor
Saskatchewan Centre for Patient-Oriented Research
Collaborator